Revised SPC: XGEVA (denosumab) -

Revised SPC: XGEVA (denosumab)
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Cancers | Musculo-skeletal disorders | Oral and dental health
Summary
Denosumab is now contraindicated in patients with unhealed lesions from dental or oral surgery. Information added to SPC about jaw osteonecrosis events over time in patients with non-metastatic prostate cancer,
UKMi comment
Patient reminder cards about the risk of osteonecrosis of the jaw are being introduced. More information is available from MHRA drug safety bulletin at the link below.
Related links: MHRA Advice